PPT-DTG vs LPV/r (DAWNING): Efficacy

by Baseline NRTI Resistance and SecondLine NRTI Use Dannae Brown 1 Ruolan Wang 2 Mark Underwood 2 Judy Hopking 3 Maria Claudia Nascimento 4 Michael Aboud 4 Jörg. fu berlinde httpwwwRalfSchwarzerde Introduction Nutrition Self Efficacy Physical Exercise Self Efficacy Alcohol Resistance Self Efficacy Localizer Performance without Vertical Guidance (LP) and Lateral Navigation (LNAV)LPs are non-precision approaches with WAAS lateral guidance. They are added in locations where terrain or obstructions Author: Henry Ernest . Nichol, . Copyright:Public. . Domain. CCLI Song No.:29420. Topic:The. World For God,. Verse 1. We've a story to tell to the nations. That shall turn their hearts to the right,. STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . Data . from other . cohorts and . regions to guide . decisions around the use of DTG . Meg Doherty MD MPH PhD. 24 July 2018. WHO HQ. New . findings informed DTG safety . profile . among . women of child bearing potential . Action. Improving Access to Optimized Treatment . for Children . Living with HIV. Melbourne, 22 July 2014. Marc Lallemant & Janice Lee. DNDi. mlallemant@dndi.org. Malaria. Leishmaniasis. Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles Figure 1 displays a substantial loss of 99 and 100 LPV service across much of the eastern half of CONUS mpling LPV coverage trend from Week 1376 Figure 3 150 Instantaneous LPV Coverage for Week 13 Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. GEMINI 1 and GEMINI 2: Week 48 Data. DTG + 3TC . versus . DTG + TDF-FTC as Initial ART. GEMINI 1 and 2: Background. Source: Cahn P, et al. Lancet. 2019;393:143-55.. Study Design: GEMINI 1 and 2. Background. ARV . strategies. DOR > DRV/r 1st line. (DRIVE-FORWARD W96). DTG. monotherapy. Switch PI/r-DTG (NEAT22). Switch RPV+DTG . (SWORD). Test and . Treat. D/C/F/TAF . (DIAMOND). −10% noninferiority margin for individual studies.. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. HIV-NAT . 017. SQV and . LPV-RTV . in Treatment-Experienced Children . HIV-NAT . 017: . Study . Design. Source: . Kosalaraksa. P, et al. . Pediatr. Infect Dis J. . 2008;27:. 623-8. . SQV + LPV-RTV +/- 3TC.